Trial · NCT03221426
Adverse events2,310
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,310
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab + XP/FP | 165 | 399 | 228 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + XP/FP | 158 | 400 | 210 |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab + FLOT Cohort | 25 | 99 | 46 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + FLOT Cohort | 26 | 103 | 49 |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab + XP/FP and Pembrolizumab + FLOT Combined | 190 | 498 | 274 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + XP/FP and Placebo + FLOT Combined | 184 | 503 | 259 |
| other | Leukopenia | Blood and lymphatic system disorders | Pembrolizumab + XP/FP | 16 | 399 | 27 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo + XP/FP | 23 | 400 | 37 |
| other | Leukopenia | Blood and lymphatic system disorders | Pembrolizumab + FLOT Cohort | 5 | 99 | 5 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo + FLOT Cohort | 5 | 103 | 6 |
| other | Leukopenia | Blood and lymphatic system disorders | Pembrolizumab + XP/FP and Pembrolizumab + FLOT Combined | 21 | 498 | 32 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo + XP/FP and Placebo + FLOT Combined | 28 | 503 | 43 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab + XP/FP | 114 | 399 | 198 |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo + XP/FP | 111 | 400 | 192 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab + FLOT Cohort | 27 | 99 | 44 |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo + FLOT Cohort | 23 | 103 | 36 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab + XP/FP and Pembrolizumab + FLOT Combined | 141 | 498 | 242 |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo + XP/FP and Placebo + FLOT Combined | 134 | 503 | 228 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pembrolizumab + XP/FP | 19 | 399 | 22 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo + XP/FP | 26 | 400 | 32 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03221426/events